Is it possible to provide a prognosis after radical prostatectomy for prostate cancer by means of a PSA regression model?

International Journal of Biological Markers

Volumn 20, Issue 2, 2005, Pages 112-118

  May, Matthias ^a   Gunia, S ^a   Helke, C ^a   Braun, K P ^a   Pickenhain, S ^b   Hoschke, B ^a  

^a Carl Thiem Hospital   (Germany)

^b BRANDENBURG UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Prognosis; PSA half life; Radical prostatectomy; Two compartment model

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DIAGNOSTIC VALUE; DISEASE COURSE; FOLLOW UP; HALF LIFE TIME; HEALTH CARE FACILITY; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 22944449330     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.5665     Document Type: Article

References (15)

1. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-16.
2. Oesterling JE, Chan DW, Epstein JI, et al. Prostate specific antigen in the preoperative and post-operative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988; 139: 766-72.
3. Pontes JE, Jabalameli P, Montie J, Foemmel R, Howard PD, Boyett J. Prognostic implications of disappearance rate of biologic markers following radical prostatectomy. Urology 1990; 36: 415-9.
4. Lein M, Brux B, Jung K, et al. Elimination of serum free and total prostate-specific antigen after radical retropubic prostatectomy. Eur J Clin Chem Clin Biochem 1997; 35: 591-5.
5. Semjonow A, Hamm M, Rathert P. Prediction of tumor recurrence after radical prostatectomy using elimination kinetics of prostate-specific antigen. World J Urol 1993; 11: 218-20.
6. Brändle E, Gottfried HW, Maier S, Flohr P, Steinbach G, Hautmann RE. [Is radical prostatectomy a suitable model for determination of PSA half-life?] Urologe A 1995; 34: 419-23 (in German).
7. Brändle E, Hautmann O, Bachem M, et al. Serum half-life time determination of free and total prostate-specific antigen following radical prostatectomy - a critical assessment. Urology 1999; 53: 722-30.
8. May M, Helke C, Nitzke T, Seehafer M, Vogler H, Hoschke B. Diagnostic value of tumour marker regression models in stage 1 marker-positive testicular cancer. Urol Int 2004; 73: 329-36.
9. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004; 172: 910-4.
10. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555-65.
11. Salomon L, Anastasiadis AG, Johnson CW, et al. Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression. Urology 2003; 62: 304-9.
12. Bianco FJ Jr, Wood DP Jr, Cher ML, Powell IJ, Souza JW, Pontes JF. Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer. Clin Prostate Cancer 2003; 1: 242-7.
13. Fichtner J, Miller K. [Management of patients with increasing PSA values after curative therapy]. Urologe A 2000; 39: 475-82 (in German).
14. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7.
15. Oberpenning F, Schmid HP, Fuchs-Surdel W, Hertle L, Semjonow A. The impact of intraoperative manipulation of the prostate on total and free prostate-specific antigen. Int J Biol Markers 2002; 17: 154-60.